These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 1447736

  • 1. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 2. Synthesis and biological activity of 8-(benzenesulfonamido)-7-(3-pyridinyl)octaonic acid and related compounds.
    Main AJ, Goldstein R, Cohen DS, Furness P, Lee W.
    J Med Chem; 1992 Nov 13; 35(23):4362-5. PubMed ID: 1447736
    [Abstract] [Full Text] [Related]

  • 2. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 3. Pyridinylalkyl-substituted 8-[(arylsulfonyl)amino]octanoic acids.
    Main AJ, Bhagwat SS, Boswell C, Goldstein R, Gude C, Cohen DS, Furness P, Lee W, Louzan M.
    J Med Chem; 1992 Nov 13; 35(23):4366-72. PubMed ID: 1447737
    [Abstract] [Full Text] [Related]

  • 3. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 4. 8-[[(4-Chlorophenyl)sulfonyl]amino]-4-(3-(3-pyridinyl) propyl)octanoic acid and analogs.
    Bhagwat SS, Gude C, Boswell C, Contardo N, Cohen DS, Dotson R, Mathis J, Lee W, Furness P, Zoganas H.
    J Med Chem; 1992 Nov 13; 35(23):4373-83. PubMed ID: 1447738
    [Abstract] [Full Text] [Related]

  • 4. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 5. Synthesis and evaluation of enantiomers of 8-[[(4-chlorophenyl)sulfonyl]amino]-4-(3-pyridinylalkyl)octanoic acid.
    Bhagwat SS, Gude C, Cohen DS, Dotson R, Mathis J, Lee W, Furness P.
    J Med Chem; 1993 Jan 22; 36(2):205-10. PubMed ID: 8423593
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and thromboxane A2 antagonistic activity of [[1-aryl(or benzyl)-1-(benzenesulfonamido)methyl]phenyl]alkanoic acid derivatives.
    Sakurai S, Ogawa N, Suzuki T, Kato K, Ohashi T, Yasuda S, Kato H, Ito Y.
    Chem Pharm Bull (Tokyo); 1996 Apr 22; 44(4):765-77. PubMed ID: 8681409
    [Abstract] [Full Text] [Related]

  • 6. Design, synthesis, and pharmacology of 3-substituted sodium azulene-1-sulfonates and related compounds: non-prostanoid thromboxane A2 receptor antagonists.
    Tomiyama T, Yokota M, Wakabayashi S, Kosakai K, Yanagisawa T.
    J Med Chem; 1993 Apr 02; 36(7):791-800. PubMed ID: 8464032
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM, Wu TS, Teng CM.
    Br J Pharmacol; 1994 Mar 02; 111(3):906-12. PubMed ID: 8019768
    [Abstract] [Full Text] [Related]

  • 8. Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
    Cozzi P, Giordani A, Menichincheri M, Pillan A, Pinciroli V, Rossi A, Tonani R, Volpi D, Tamburin M, Ferrario R.
    J Med Chem; 1994 Oct 14; 37(21):3588-604. PubMed ID: 7932586
    [Abstract] [Full Text] [Related]

  • 9. New tetrahydronaphthalene derivatives as combined thromboxane receptor antagonists and thromboxane synthase inhibitors.
    Cimetière B, Dubuffet T, Landras C, Descombes JJ, Simonet S, Verbeuren TJ, Lavielle G.
    Bioorg Med Chem Lett; 1998 Jun 02; 8(11):1381-6. PubMed ID: 9871770
    [Abstract] [Full Text] [Related]

  • 10. The thromboxane A2/prostaglandin endoperoxide receptor antagonist activity of CV-4151, a thromboxane A2 synthetase inhibitor.
    Imura Y, Terashita Z, Shibouta Y, Nishikawa K.
    Eur J Pharmacol; 1988 Mar 15; 147(3):359-65. PubMed ID: 2967770
    [Abstract] [Full Text] [Related]

  • 11. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
    Soyka R, Guth BD, Weisenberger HM, Luger P, Müller TH.
    J Med Chem; 1999 Apr 08; 42(7):1235-49. PubMed ID: 10197967
    [Abstract] [Full Text] [Related]

  • 12. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 1. (+/-)-(3-pyridinylbicycloheptyl)alkanoic acids.
    Bhagwat SS, Gude C, Cohen DS, Lee W, Furness P, Clarke FH.
    J Med Chem; 1991 Jun 08; 34(6):1790-7. PubMed ID: 1829485
    [Abstract] [Full Text] [Related]

  • 13. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.
    Ohkubo S, Nakahata N, Ohizumi Y.
    Br J Pharmacol; 1996 Mar 08; 117(6):1095-104. PubMed ID: 8882602
    [Abstract] [Full Text] [Related]

  • 14. Thromboxane modulating agents. 3. 1H-imidazol-1-ylalkyl- and 3-pyridinylalkyl-substituted 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists.
    Dickinson RP, Dack KN, Long CJ, Steele J.
    J Med Chem; 1997 Oct 10; 40(21):3442-52. PubMed ID: 9341919
    [Abstract] [Full Text] [Related]

  • 15. Synthesis of [[(benzenesulfonamido)alkyl]phenyl]alkanoic acid derivatives containing pyridyl or imidazolyl groups and their thromboxane A2 receptor antagonistic and thromboxane A2 synthase inhibitory activities.
    Sakurai S, Ogawa N, Suzuki T, Kato K, Ohashi T, Yasuda S, Kato H.
    Chem Pharm Bull (Tokyo); 1996 Aug 10; 44(8):1510-20. PubMed ID: 8795270
    [Abstract] [Full Text] [Related]

  • 16. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R, Nenci GG, Gresele P.
    J Pharmacol Exp Ther; 1995 Dec 10; 275(3):1497-505. PubMed ID: 8531121
    [Abstract] [Full Text] [Related]

  • 17. Evidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2 alpha.
    Krauss AH, Woodward DF, Gibson LL, Protzman CE, Williams LS, Burk RM, Gac TS, Roof MB, Abbas F, Marshall K, Senior J.
    Br J Pharmacol; 1996 Mar 10; 117(6):1171-80. PubMed ID: 8882612
    [Abstract] [Full Text] [Related]

  • 18. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS, Wharton KA, White BP, Lumley P.
    Br J Pharmacol; 1991 Feb 10; 102(2):497-505. PubMed ID: 1826620
    [Abstract] [Full Text] [Related]

  • 19. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.
    Lumley P, White BP, Humphrey PP.
    Br J Pharmacol; 1989 Jul 10; 97(3):783-94. PubMed ID: 2527074
    [Abstract] [Full Text] [Related]

  • 20. Effect of thromboxane A2 synthetase inhibition, singly and combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on inositol phospholipid turnover and on 5-HT release by washed human platelets.
    de Chaffoy de Courcelles D, De Clerck F.
    Eur J Pharmacol; 1990 Mar 13; 188(2-3):161-9. PubMed ID: 2318257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.